GrowingStockReport.com

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) and CytRx Corporation (NASDAQ:CYTR) Added to Growing Stock Report's NASDAQ Decliners Watch List.

 

New York, NY -- (ReleaseWire) -- 10/09/2013 -- Growing Stock Report expands its NASDAQ Decliners Weekly Watch List adding Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) and CytRx Corporation (NASDAQ:CYTR).

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients is currently down (-64.99%) on 100,931,289 shares traded after the company said it was putting a hold on new patient enrollment for tests on its leukemia drug Iclusig. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) is currently down (-84.25%) from its recent 52-week high which has prompted Growing Stock Report to add the stock to their NASDAQ Decliners Watch List.

Click Here to find out what other Investors are saying about Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)

CytRx Corporation (NASDAQ:CYTR) a biopharmaceutical research and development company specializing in oncology is currently down (-18.61%) on 4,441,251 shares traded after CytRx Announced Pricing of Public Offering of 10.0 Million Shares of Common Stock. CytRx Corporation (NASDAQ:CYTR) is currently down (-40.27%) from its recent 52-week high which has prompted Growing Stock Report to add the stock to their NASDAQ Decliners Watch List.

Click Here to find out what other Investors are saying about CytRx Corporation (NASDAQ:CYTR)

GrowingStockReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals GrowingStockReport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.GrowingStockReport.com

Disclosure
GrowingStockReport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit GrowingStockReport.com website, for complete risks and disclosures.

Contact Info:
Growing Stock Report
editor@GrowingStockReport.com